Carrier-free poly(glycyrrhetinic acid)-facilitated celastrol-loaded nanoparticle for high-efficiency low-toxicity treatment of rheumatoid arthritis
Source abstract
Abstract
Rheumatoid arthritis (RA) is a complex autoimmune disease associated with synovial inflammation and articular cartilage destruction. Currently, high-efficiency low-toxicity management of this intractable disease is highly urgent. Here, a drug-backboned polymer, polyglycyrrhetinic acid (PGA), was synthesized through the condensation of GA, a principal anti-inflammatory component of Glycyrrhiza glabra. PGA was then used as a therapeutic polyprodrug carrier to fabricate carrier-free PGA@Cel nanoparticles (NPs) for treating rheumatoid arthritis. The as-prepared NPs exhibited a uniformly spherical morphology with an average particle size of approximately 180 nm and a celastrol (Cel) loading capacity of around 4.5 %. Upon intravenous injection, the NPs demonstrated prolonged blood circulation, efficient accumulation at inflammatory joints through extravasation via leaky vasculature and subsequent inflammatory cell-mediated sequestration (ELVIS) effect. The present study demonstrated enhanced anti-inflammatory and rheumatic decay efficiency in rat models of antigen-induced arthritis, while simultaneously minimizing off-target toxicity. Overall, our results elucidate that this carrier-free drug-backboned nanopolydrug platform provides a promising strategy for RA therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Natural Compounds in Disease Treatment · Rheumatoid Arthritis Research and Therapies · Pharmacological Effects of Natural Compounds
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (43)
Show source-provided references
1. Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions10.1038/s41584-022-00793-5 ↗
2. PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes10.1136/ard-2022-222708 ↗
3. Recent advances in nano-targeting drug delivery systems for rheumatoid arthritis treatment10.15212/AMM-2022-0039 ↗
4. Antioxidant and antiarthritic potential of berberine: In vitro and in vivo studies10.1016/j.chmed.2023.02.007 ↗
5. Emerging nanotherapeutics alleviating rheumatoid arthritis by readjusting the seeds and soils10.1016/j.jconrel.2022.04.001 ↗
6. Rheumatoid arthritis - common origins Divergent Mechanisms10.1056/NEJMra2103726 ↗
7. Signaling pathways in rheumatoid arthritis: implications for targeted therapy10.1038/s41392-023-01331-9 ↗
8. Management of rheumatoid arthritis: an overview10.3390/cells10112857 ↗
9. Methotrexate: a detailed review on drug delivery and clinical aspects10.1517/17425247.2012.642362 ↗
10. Multifunctional nanoplatform for mild microwave-enhanced thermal, antioxidative, and chemotherapeutic treatment of rheumatoid arthritis10.1021/acsami.2c19198 ↗
11. Ultrasound-remote selected activation mitophagy for precise treatment of rheumatoid arthritis by two-dimensional piezoelectric nanosheets10.1021/acsnano.2c09834 ↗
12. Additive efficacy of a bispecific anti-TNF/IL-6 nanobody compound in translational models of rheumatoid arthritis10.1126/scitranslmed.abq4419 ↗
13. Porous silicon-based nanomedicine for simultaneous management of joint inflammation and bone erosion in rheumatoid arthritis10.1021/acsnano.2c04491 ↗
14. Metabolically engineered stem cell-derived exosomes to regulate macrophage heterogeneity in rheumatoid arthritis10.1126/sciadv.abe0083 ↗
15. Pathophysiology to advanced intra-articular drug delivery strategies: unravelling rheumatoid arthritis10.1016/j.biomaterials.2023.122390 ↗
16. Ferrihydrite nanoparticles alleviate rheumatoid arthritis by nanocatalytic antioxidation and oxygenation10.1021/acs.nanolett.3c02743 ↗
17. Treating autoimmune inflammatory diseases with an siern1-nanoprodrug that mediates macrophage polarization and blocks toll-like receptor signaling10.1021/acsnano.1c03726 ↗
18. Inflammation-instructed hierarchical delivery of il-4/mir-21 orchestrates osteoimmune microenvironment toward the treatment of rheumatoid arthritis10.1002/adfm.202101033 ↗
19. Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis10.1038/s41467-021-22454-z ↗
20. Inflammation-targeted celastrol nanodrug attenuates collagen-induced arthritis through nf-κb and notch1 pathways10.1021/acs.nanolett.0c03279 ↗
21. Nanoemulsions target to ectopic lymphoids in inflamed joints to restore immune tolerance in rheumatoid arthritis10.1021/acs.nanolett.0c05110 ↗
22. Biomimetic hybrid membrane-coated xuetongsu assisted with laser irradiation for efficient rheumatoid arthritis therapy10.1021/acsnano.1c07556 ↗
23. M2-type exosomes nanoparticles for rheumatoid arthritis therapy via macrophage re-polarization10.1016/j.jconrel.2021.11.019 ↗
24. Neuroinflammation attenuation effects by celastrol and PDIA3 in the amygdala, hippocampus and dorsal raphe nucleus of obese mice
25. Carrier-free nanomedicines for cancer treatment10.1016/j.pmatsci.2021.100919 ↗
26. Pure drug nano-assemblies: a facile carrier-free nanoplatform for efficient cancer therapy10.1016/j.apsb.2021.08.012 ↗
27. Advances and perspectives in carrier-free nanodrugs for cancer chemo-monotherapy and combination therapy10.1016/j.biomaterials.2020.120557 ↗
28. Therapeutic copolymer from salicylic acid and l-phenylalanine as a nanosized drug carrier for orthotopic breast cancer with lung metastasis10.1021/acsami.3c08608 ↗
29. Rebirth of aspirin synthesis by-product: prickly poly(salicylic acid) nanoparticles as self-anticancer drug carrier10.1002/adfm.202100805 ↗
30. Self-assembled poly(rosmarinic acid) nanoantioxidant for enhanced acute liver injury treatment10.1021/acsanm.3c02555 ↗
31. Nanodrug carrier based on poly(ursolic acid) with self-anticancer activity against colorectal cancer10.1002/adfm.201907857 ↗
32. Identification of microRNA and analysis of target genes in Panax ginseng10.1016/j.chmed.2022.08.006 ↗
33. In situ apolipoprotein E-enriched corona guides dihydroartemisinin-decorating nanoparticles towards LDLr-mediated tumor-homing chemotherapy10.1016/j.ajps.2019.05.002 ↗
34. Smart stimuli-responsive carrier-free nanoassembly of SN38 prodrug as efficient chemotherapeutic nanomedicine10.15212/AMM-2023-0003 ↗
35. Rational engineering docetaxel prodrug nanoassemblies: response modules guiding efficacy enhancement and toxicity reduction10.1021/acs.nanolett.3c00704 ↗
36. In situ low-immunogenic albumin-conjugating-corona guiding nanoparticles for tumor-targeting chemotherapy10.1039/C8BM00692J ↗
37. An ROS-responsive artesunate prodrug nanosystem co-delivers dexamethasone for rheumatoid arthritis treatment through the HIF-1α/NF-κB cascade regulation of ROS scavenging and macrophage repolarization10.1016/j.actbio.2022.08.054 ↗
38. Wnt/β-catenin signaling pathway promotes abnormal activation of fibroblast-like synoviocytes and angiogenesis in rheumatoid arthritis and the intervention of Er Miao San10.1016/j.phymed.2023.155064 ↗
39. Aminocellulose-grafted-polycaprolactone coated gelatin nanoparticles alleviate inflammation in rheumatoid arthritis: a combinational therapeutic approach10.1016/j.carbpol.2020.117600 ↗
40. Autophagy targeting nanoparticles in rheumatoid arthritis and osteoarthritis, Materials
41. Caffeic acid modified nanomicelles inhibit articular cartilage deterioration and reduce disease severity in experimental inflammatory arthritis10.1021/acsnano.2c07027 ↗
42. Enzyme targeted delivery of sivelestat loaded nanomicelle inhibits arthritic severity in experimental arthritis10.1016/j.lfs.2023.122206 ↗
43. Emerging well-tailored nanoparticulate delivery system based on in situ regulation of the protein corona10.1016/j.jconrel.2020.01.007 ↗